 MELBOURNE, Australia, Feb. 24, 2021 GLOBE NEWSWIRE -- Opthea Limited ASX:OPT; Nasdaq: OPT, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces that it has finalized the protocol study designs and key start-up activities in readiness for the initiation of the Phase 3 ShORe and COAST pivotal clinical trials of OPT-302 in wet age-related macular degeneration AMD. 